journal
MENU ▼
Read by QxMD icon Read
search

Clinical and Molecular Hepatology

journal
https://www.readbyqxmd.com/read/30227702/assessment-of-fibrotic-burden-among-chronic-hepatitis-b-virus-infected-patients-with-normal-transaminase-level
#1
Mi Young Jeon, Beom Kyung Kim, Seung Up Kim
No abstract text is available yet for this article.
September 19, 2018: Clinical and Molecular Hepatology
https://www.readbyqxmd.com/read/30184617/viekira-pak-associated-drug-induced-interstitial-lung-disease-case-series-with-systematic-review-of-literature
#2
Yu Jun Wong, Si Yuan Chew, John Chen Hsiang, Prem Harichander Thurairajah, Rahul Kumar, Eng Kiong Teo, Roshni Sadashiv Gokhale, Imran Bin Mohamed Noor, Jessica Tan
No abstract text is available yet for this article.
September 6, 2018: Clinical and Molecular Hepatology
https://www.readbyqxmd.com/read/30149691/biochemical-profile-in-an-infant-with-neonatal-hemochromatosis-shows-evidence-of-impairment-of-mitochondrial-long-chain-fatty-acid-oxidation
#3
Karina Lucio de Medeiros Bastos, Caio Robledo Quaio, Fabiana Roberto Lima, Iana Manuelle Araújo, Candice Alves Tavares Araújo, Flávia Balbo Piazzon, Ismael Dale Cotrim Guerreiro da Silva, Gabriel Nuncio Benevides, Ana Cristina Tannuri, Uenis Tannuri, Ramiro Anthero Azevedo, Chong Ae Kim
No abstract text is available yet for this article.
August 28, 2018: Clinical and Molecular Hepatology
https://www.readbyqxmd.com/read/30145855/cardiac-diastolic-dysfunction-predicts-poor-prognosis-in-patients-with-decompensated-liver-cirrhosis
#4
Soon Kyu Lee, Myeong Jun Song, Seok Hwan Kim, Hyo Jun Ahn
Background/Aims: Left ventricular diastolic dysfunction (LVDD) is an early manifestation of cardiac dysfunction in patients with liver cirrhosis (LC). However, the effect of LVDD on survival has not been clarified, especially in decompensated LC. Methods: We prospectively enrolled 70 patients with decompensated LC, including ascites or variceal bleeding, at Daejeon St. Mary's Hospital from April 2013 to April 2015. The cardiac function of these patients was evaluated using 2D echocardiography with tissue Doppler imaging...
August 27, 2018: Clinical and Molecular Hepatology
https://www.readbyqxmd.com/read/30086613/recent-research-trends-and-updates-on-nonalcoholic-fatty-liver-disease
#5
Jeong-Ju Yoo, Won Kim, Moon Young Kim, Dae Won Jun, Sang Gyune Kim, Jong-Eun Yeon, Jin Woo Lee, Yong Kyun Cho, Sang Hoon Park, Joo Hyun Sohn
Nonalcoholic fatty liver disease (NAFLD), together with metabolic syndrome and obesity, has shown a rapid increase in prevalence worldwide and is emerging as a major cause of chronic liver disease and liver transplantation. Among the various phenotypes of NAFLD, nonalcoholic steatohepatitis (NASH) is highly likely to progress to development of end-stage liver disease and cardiometabolic disease, resulting in liver-related and non-liver-related mortality. Nonetheless, there is no standardized pharmacotherapy against NASH and many drugs are under development in ongoing clinical trials...
August 8, 2018: Clinical and Molecular Hepatology
https://www.readbyqxmd.com/read/30068065/the-association-of-leptin-with-severity-of-non-alcoholic-fatty-liver-disease-a-population-based-study
#6
Laura Rotundo, Alana Persaud, Mirela Feurdean, Sushil Ahlawat, Hyun-Seok Kim
Background/Aims: Leptin is associated with metabolic disorders, which predispose one to non-alcoholic fatty liver disease (NAFLD). The role of leptin in NAFLD pathogenesis is not fully understood. We aim to investigate the association between serum leptin level and severity of NAFLD using U.S. nationally representative data. Methods: Data were obtained from the United States Third National Health and Nutrition Examination Survey. NAFLD was defined by ultrasound detection and severity of hepatic steatosis in the absence of other liver diseases...
August 2, 2018: Clinical and Molecular Hepatology
https://www.readbyqxmd.com/read/29969885/characterization-and-evaluation-of-liver-fibrosis-grade-in-patients-with-chronic-hepatitis-b-virus-infection-and-normal-transaminases
#7
San Juan López Cristina, Casado Martín Marta, González Sánchez Mercedes, Porcel Martín Almudena, Hernández Martínez Álvaro, Vega Sáenz Jose Luis, Parrón Carreño Tesifón
Backgrounds/Aims: The objective of our study was to determine the epidemiological, laboratory, and serological characteristics of patients with chronic hepatitis B virus (HBV) infection and normal transaminases. The study also aimed to evaluate liver damage by measuring the liver fibrosis (LF) grade and to identify possible factors associated with the presence of fibrosis. Methods: A retrospective observational study was conducted in patients with chronic HBV infection and classified as inactive carriers or immune-tolerant...
July 4, 2018: Clinical and Molecular Hepatology
https://www.readbyqxmd.com/read/29940720/effect-of-antiviral-therapy-in-reducing-perinatal-transmission-of-hepatitis-b-virus-and-maternal-outcomes-after-discontinuing-them
#8
Kwang Il Seo, Si Hyun Bae, Pil Soo Sung, Chung-Hwa Park, Hae Lim Lee, Hee Yeon Kim, Hye Ji Kim, Bo Hyun Jang, Jeong Won Jang, Seung Kew Yoon, Jong Young Choi, In-Yang Park, Juyoung Lee, Hyun Seung Lee, Sa-Jin Kim, Jung Hyun Kwon, U Im Chang, Chang Wook Kim, Se Hyun Jo, Young Lee Young Lee, Fisseha Tekle, Jong-Hyun Kim
Background/Aims: There have been numerous efforts to reduce mother-to-child transmission (MTCT) of hepatitis B virus (HBV) with antiviral agents during pregnancy. However, there are limited data regarding the outcomes of pregnant women after delivery. This study was performed to evaluate the efficacy of antiviral agents in preventing MTCT of HBV and maternal long-term outcomes. Methods: The HBV-infected pregnant women treated with antiviral agents to prevent MTCT were retrospectively reviewed...
June 26, 2018: Clinical and Molecular Hepatology
https://www.readbyqxmd.com/read/30200750/does-the-old-fashioned-sofosbuvir-plus-ribavirin-treatment-in-genotype-2-chronic-hepatitis-c-patients-still-works-for-koreans
#9
Jong Eun Yeon
No abstract text is available yet for this article.
September 2018: Clinical and Molecular Hepatology
https://www.readbyqxmd.com/read/30196651/combination-of-synbiotic-and-sitagliptin-in-nonalcoholic-fatty-liver-disease-is-it-better-than-sitagliptin-alone
#10
Yong Kyun Cho
No abstract text is available yet for this article.
September 2018: Clinical and Molecular Hepatology
https://www.readbyqxmd.com/read/30196650/prognostic-implications-of-trunk-muscle-mass-in-liver-cirrhosis
#11
Jimin Han, Won Kim
No abstract text is available yet for this article.
September 2018: Clinical and Molecular Hepatology
https://www.readbyqxmd.com/read/30092624/2017-kasl-clinical-practice-guidelines-management-of-hepatitis-c-treatment-of-chronic-hepatitis-c
#12
(no author information available yet)
No abstract text is available yet for this article.
September 2018: Clinical and Molecular Hepatology
https://www.readbyqxmd.com/read/29991196/kasl-clinical-practice-guidelines-for-liver-cirrhosis-ascites-and-related-complications
#13
(no author information available yet)
No abstract text is available yet for this article.
September 2018: Clinical and Molecular Hepatology
https://www.readbyqxmd.com/read/29890569/combined-effects-of-synbiotic-and-sitagliptin-versus-sitagliptin-alone-in-patients-with-nonalcoholic-fatty-liver-disease
#14
Saba Sayari, Hassan Neishaboori, Maryam Jameshorani
BACKGROUND/AIMS: Non-alcoholic fatty liver disease (NAFLD) is one of the most prevalent chronic liver diseases in recent years. The aim of this study was to evaluate the effects of sitagliptin with and without a synbiotic supplement in the treatment of patients with NAFLD. METHODS: In total, 138 NAFLD patients aged 18-60 years were enrolled in the study. Patients were randomized to one of the following treatments for 16 weeks: Group I (n=68), sitagliptin 50 mg daily plus placebo (one capsule per day) or group II (n=70) sitagliptin 50 mg daily plus synbiotic (one capsule per day)...
September 2018: Clinical and Molecular Hepatology
https://www.readbyqxmd.com/read/29886705/transarterial-embolization-for-the-treatment-of-complicated-liver-hemangiomas-a-report-of-two-cases-and-review-of-the-literature
#15
Maria Kalogirou, Danai Chourmouzi, Ioannis Dedes, Stefania Kiapidou, Evangelos Akriviadis, Emmanouil Sinakos
No abstract text is available yet for this article.
September 2018: Clinical and Molecular Hepatology
https://www.readbyqxmd.com/read/29865774/efficacy-and-safety-of-sofosbuvir-plus-ribavirin-for-korean-patients-with-hepatitis-c-virus-genotype-2-infection-a-retrospective-multi-institutional-study
#16
Young Min Kim, Suk Bae Kim, Il Han Song, Sae Hwan Lee, Hong Soo Kim, Tae Hee Lee, Young Woo Kang, Seok Hyun Kim, Byung Seok Lee, Hee Bok Chae, Myeong Jun Song, Ji Woong Jang, Soon Young Ko, Jae Dong Lee
BACKGROUND/AIMS: Sofosbuvir plus ribavirin is a standard treatment for patients infected with chronic hepatitis C virus (HCV) genotype 2 in Korea. The purpose of this study was to examine the efficacy and safety of this treatment in Korean patients with chronic HCV genotype 2 infection. METHODS: We retrospectively analyzed clinical data of patients treated with sofosbuvir plus ribavirin for chronic HCV genotype 2 from May 2016 to December 2017 at eight hospitals located in the Daejeon-Chungcheong area...
September 2018: Clinical and Molecular Hepatology
https://www.readbyqxmd.com/read/29716179/recent-update-of-the-2017-korean-association-for-the-study-of-the-liver-kasl-treatment-guidelines-of-chronic-hepatitis-c-comparison-of-guidelines-from-other-continents-2017-aasld-idsa-and-2016-easl
#17
Jong Eun Yeon
The paradigm for the treatment of chronic hepatitis C (CHC) has been changed due to the development of direct acting antivirals (DAAs) of hepatitis C virus (HCV). The high sustained virologic response rate and ease of administration makes the DAAs approach ideal to contribute to the complete eradication of HCV. Currently, treatment options for individual patients vary depending on the genotype or subtype of HCV, presence or absence of liver cirrhosis, previous experience of antiviral treatment or resistance associated substitutions...
September 2018: Clinical and Molecular Hepatology
https://www.readbyqxmd.com/read/29706058/clinical-usefulness-of-psoas-muscle-thickness-for-the-diagnosis-of-sarcopenia-in-patients-with-liver-cirrhosis
#18
Dae Hoe Gu, Moon Young Kim, Yeon Seok Seo, Sang Gyune Kim, Han Ah Lee, Tae Hyung Kim, Young Kul Jung, Altay Kandemir, Ji Hoon Kim, Hyunggin An, Hyung Joon Yim, Jong Eun Yeon, Kwan Soo Byun, Soon Ho Um
BACKGROUND/AIMS: The most widely used method for diagnosing sarcopenia is the skeletal muscle index (SMI). Several studies have suggested that psoas muscle thickness per height (PMTH) is also effective for detecting sarcopenia and predicting prognosis in patients with cirrhosis. The aim of this study was to evaluate the optimal cutoff values of PMTH for detecting sarcopenia in cirrhotic patients. METHODS: All cirrhotic patients who underwent abdominal computed tomography (CT) scan including L3 and umbilical levels for measuring SMI and transverse psoas muscle thickness, respectively, were included...
September 2018: Clinical and Molecular Hepatology
https://www.readbyqxmd.com/read/29526079/interferon-free-treatment-for-hepatitis-c-virus-infection-induces-normalization-of-extrahepatic-type-i-interferon-signaling
#19
Pil Soo Sung, Eun Byul Lee, Dong Jun Park, Angelo Lozada, Jeong Won Jang, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon
BACKGROUND/AIMS: Hepatitis C virus (HCV) replicates in the peripheral blood mononuclear cells (PBMCs), leading to the production of type I interferons (IFNs). It is well known that the gene expression profile of PBMC is similar to that of the liver. The present study explored the dynamic gene expression profile of PBMCs collected from HCV-infected patients undergoing direct-acting antiviral (DAA) therapy. METHODS: A prospective cohort comprising 27 patients under DAA therapy was formed...
September 2018: Clinical and Molecular Hepatology
https://www.readbyqxmd.com/read/29961305/journal-metrics-of-clinical-and-molecular-hepatology-based-on-the-web-of-science-core-collection
#20
Sun Huh
Background/Aims: Eight years have passed since Clinical and Molecular Hepatology changed its language policy to English-only in September 2010. The journal has been included in PubMed Central since September 2010. Present title continues the Korean Journal of Hepatology since June 2012. It has been indexed in the Web of Science Core Collection as an Emerging Sources Citation Index journal since 2015. I sought to determine whether the change in language policy was successful based on journal metrics...
June 2018: Clinical and Molecular Hepatology
journal
journal
44096
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"